PRIMA BIOMED ANNOUNCES FIRST CLINICAL DATA FROM COMBINATION OF IMP321 WITH ANTI-PD1

PRIMA BIOMED ANNOUNCES DATA FROM IMP321 AIPAC CLINICAL TRIAL IN BREAST CANCER

PRIMA BIOMED ENTERS INTO SALE AND LICENSING AGREEMENT WITH SYDYS TO ADVANCE CVAC™ PROGRAM

PRIMA TO PRESENT AT 2016 SOCIETY FOR IMMUNOTHERAPY OF CANCER CONFERENCE

PRIMA ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT ESMO SYMPOSIUM ON IMMUNO-ONCOLOGY

Operational Update

PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY

PRIMA BIOMED COLLABORATES IN INVESTIGATOR SPONSORED NEW CLINICAL TRIAL FOR IMP321 IN SOLID TUMORS

PRIMA BIOMED TO MAINTAIN NASDAQ LISTING

PRIMA BIOMED ANNOUNCES FIRST SAFETY, PHARMACOKINETICS AND IMMUNO-MONITORING DATA FROM PHASE IIB CLINICAL TRIAL OF IMP321

IMP321 SAFETY AND IMMUNE MONITORING DATA PUBLISHED IN CLINICAL CANCER RESEARCH JOURNAL

PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY

Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial

JAPANESE PATENT GRANTS FOR IMP321 IN CANCER

US PATENT GRANTS FOR IMP731 ANTIBODY

PRIMA BIOMED INITIATES PHASE I MELANOMA STUDY IN AUSTRALIA